Screener
TG Therapeutics TGTX Product — Accounts Receivable Net
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNet.
The source filing: TG Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025955
As of June 30, 2026, gross-to-net accruals of approximately $29.2 million and $69.3 million are included on the condensed consolidated balance sheets within accounts receivable, net, and accounts payable and accrued expenses, respectively. As of June 30, 2025, gross-to-net accruals of approximately $16.1 million and $33.3 million are included on the condensed consolidated balance sheets within accounts receivable, net, and accounts payable and accrued expenses, respectively.
Document
FAQ
- What is TG Therapeutics's product — accounts receivable net?
- TG Therapeutics (TGTX) reported product — accounts receivable net of $29.2M in Q2 2026.
- What does product — accounts receivable net mean?
- This represents the balance of payments owed to the company by customers for product shipments, net of any allowances for doubtful accounts. It reflects the efficiency of the company's credit and collection processes within its commercial segment. Monitoring this helps assess the liquidity of the company's product-related assets.
Ask your AI about TG Therapeutics's product — accounts receivable net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude